Retatrutide vs MOTS-c
Both Retatrutide and MOTS-c are used for metabolic. Here's how their evidence, dosing, and regulatory status actually compare.
Retatrutide
Evidence ARetatrutide (LY3437943)
Triple agonist at GLP-1, GIP, and glucagon receptors. Phase 2 produced 24.2% mean weight reduction at 48 weeks — the highest ever in a clinical obesity trial.
View full Retatrutide profile →MOTS-c
Evidence BMitochondrial-derived peptide MOTS-c
A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.
View full MOTS-c profile →Side-by-Side
| Attribute | Retatrutide | MOTS-c |
|---|---|---|
| Evidence Grade | A | B |
| FDA Status | Not FDA-approved — Phase 3 trials (TRIUMPH program) for obesity | Not FDA-approved — research peptide; multiple early-phase clinical trials |
| Typical Dose | Trial range: 1–12 mg weekly (subcutaneous) | 5–10 mg, 2–3 times weekly (subcutaneous) |
| Clinics Indexed | 12 | 22 |
| Categories | weight-loss, metabolic | metabolic, longevity |
Key reported benefits — Retatrutide
- ✓Highest reported weight loss
- ✓Triple incretin/glucagon mechanism
- ✓Metabolic improvement
Key reported benefits — MOTS-c
- ✓Insulin sensitivity
- ✓Exercise capacity
- ✓Metabolic flexibility
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.